{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:25:34Z","timestamp":1772753134998,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Marcus Foundation"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA32102"],"award-info":[{"award-number":["CA32102"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA38926"],"award-info":[{"award-number":["CA38926"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA105409"],"award-info":[{"award-number":["CA105409"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA35431"],"award-info":[{"award-number":["CA35431"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA45560"],"award-info":[{"award-number":["CA45560"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA20319"],"award-info":[{"award-number":["CA20319"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA13612"],"award-info":[{"award-number":["CA13612"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA46441"],"award-info":[{"award-number":["CA46441"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA45808"],"award-info":[{"award-number":["CA45808"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA45461"],"award-info":[{"award-number":["CA45461"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA67575"],"award-info":[{"award-number":["CA67575"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA58882"],"award-info":[{"award-number":["CA58882"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA35128"],"award-info":[{"award-number":["CA35128"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA37981"],"award-info":[{"award-number":["CA37981"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA46282"],"award-info":[{"award-number":["CA46282"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA35421"],"award-info":[{"award-number":["CA35421"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA76132"],"award-info":[{"award-number":["CA76132"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA58723"],"award-info":[{"award-number":["CA58723"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA16385"],"award-info":[{"award-number":["CA16385"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute US","doi-asserted-by":"publisher","award":["CA42777"],"award-info":[{"award-number":["CA42777"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ejca.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T12:30:11Z","timestamp":1396614611000},"page":"1638-1648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904"],"prefix":"10.1016","volume":"50","author":[{"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Delmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Bonebrake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garnet L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Setsuko K.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurie","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.03.005_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2014.03.005_b0010","first-page":"15","article-title":"Vascular endothelial growth factor and the regulation of angiogenesis","volume":"55","author":"Ferrara","year":"2000","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2014.03.005_b0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/35040684","article-title":"Developmental biology. One cell, two fates","volume":"408","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2014.03.005_b0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/80430","article-title":"VEGF gene therapy: stimulating angiogenesis or angioma-genesis?","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2014.03.005_b0030","first-page":"385","article-title":"Vascular permeability factor, tumor angiogenesis and stroma generation","volume":"14","author":"Senger","year":"1994","journal-title":"Invasion Metastasis"},{"key":"10.1016\/j.ejca.2014.03.005_b0035","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A","article-title":"Vascular endothelial growth factor expression in early stage ovarian carcinoma","volume":"80","author":"Paley","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2014.03.005_b0045","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ygyno.2005.03.004","article-title":"LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)","volume":"97","author":"So","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ijc.21421","article-title":"Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases","volume":"118","author":"Wang","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2014.03.005_b0055","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0060","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.03.005_b0065","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.03.005_b0070","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1200\/JCO.2012.41.9242","article-title":"Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies","volume":"30","author":"Bottsford-Miller","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0075","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0085","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0090","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0095","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1158\/1078-0432.CCR-04-1923","article-title":"A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer","volume":"11","author":"Miller","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0100","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1200\/JCO.2007.12.3083","article-title":"Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","volume":"25","author":"Arnold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2011.12.013","article-title":"Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study","volume":"56","author":"Hsu","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2014.03.005_b0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"de Boer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2014.03.005_b0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2014.03.005_b0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0135","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.10.5122","article-title":"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer","volume":"25","author":"Heymach","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0145","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s10637-013-0011-3","article-title":"Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I\/II study of the AGO Study Group (AGO-OVAR 2.13)","volume":"31","author":"Harter","year":"2013","journal-title":"Invest New Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2014.03.005_b0150","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/sj.bjc.6602604","article-title":"ZD6474\u2013clinical experience to date","volume":"92","author":"Heymach","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2014.03.005_b0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.CCR-09-2308","article-title":"Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0160","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/JTO.0b013e31828d08ae","article-title":"Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial","volume":"8","author":"Tsao","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2010.05.005","article-title":"A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)","volume":"118","author":"Hirte","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0170","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.03.005_b0175","first-page":"182","article-title":"Health care quality perceived by the patients in an urban health centre in a coruna","volume":"22","author":"Gomez-Besteiro","year":"2012","journal-title":"Enferm Clin"},{"issue":"4","key":"10.1016\/j.ejca.2014.03.005_b0180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bbrc.2013.06.030","article-title":"IGF-1R and ErbB3\/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model","volume":"436","author":"Jia","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.ejca.2014.03.005_b0185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ccr.2009.12.047","article-title":"An activated ErbB3\/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells","volume":"17","author":"Sheng","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2014.03.005_b0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrclinonc.2013.102","article-title":"Pazopanib in ovarian cancer delays progression","volume":"10","author":"From ASCO-gynaecological cancer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2014.03.005_b0195","series-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial","author":"Ledermann","year":"2013"},{"key":"10.1016\/j.ejca.2014.03.005_b0200","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm1294","article-title":"Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells","volume":"11","author":"Mizukami","year":"2005","journal-title":"Nat Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914002482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914002482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T06:38:14Z","timestamp":1565332694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914002482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0959804914002482"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.03.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}